Boston, MA (PRWEB) March 18, 2015 In the vast flow of new scientific research, discoveries, and information, it is not uncommon for important scientific advances to go unappreciated, or even just unnoticed, for surprisingly long periods of time. The Boston stem cell medicine technology start-up company, Asymmetrex is working to make sure that its growing portfolio of adult tissue stem cell technology patents obtains wide notice, appreciation, and investment. In late 2014, the company started a digital media campaign to achieve greater visibility for its patented technologies that address the major barriers to greater progress in stem cell medicine. These include technologies for identifying, counting, and mass-producing adult tissue stem cells. The two presentations scheduled for the 5th World Congress on Cell and Stem Cell Research in Chicago continue Asymmetrexs efforts to better inform medical, research, and industrial communities focused on advancing stem cell medicine of the companys vision for implementation of its unique technologies. Asymmetrex holds patents for the only method described for routine production of natural human tissue stem cells that retain their normal function. The company also holds patents for biomarkers that can be used to count tissue stem cells for the first time. The companys most … Continue reading →

Stem cell therapy and me1 Walk without support. By: drabhijitshendeji … Continue reading →

The Alpha Clinic for Cell Therapy and Innovation | City of Hope A new grant to City of Hope from the California Institute for Regenerative Medicine (CIRM) will make it possible for novel stem cell based therapies developed here at City of Hope to... By: City of Hope … Continue reading →

A human embryonic stem cell line derived at Stanford University.(REUTERS/Julie Baker/Stanford University School of Medicine/California Institute for Regenerative Medicine/Handout) Type 2 diabetes is marked by insulin resistance, or the bodys inability to store sugar and convert it into carbohydrates for energy. Overcoming that resistance is the main hurdle scientists face in creating new treatment for the condition, but researchers in Canada have found a promising means for doing so: combining stem cell therapy and antidiabetic medication. Type 2 diabetes accounts for nearly 95 percent of the 400 million diabetes cases worldwide. Current treatment often involves imprecise insulin injection, and can produce side effects like unwanted weight gain, gastrointestinal issues and low blood glucose levels. Eighty percent of Type 2 diabetes patients are overweight. In the study, published Thursday in the journal Stem Cell Reports, scientists observed that transplanting pancreatic stem cells derived from human cells into mice with Type 2 diabetes symptoms, then administering common antidiabetic drugs, improved the mices glucose metabolism, body weight and insulin sensitivity three hallmark problems associated with the condition. There have been similar reports looking at treatment of type 1 diabetes by stem cell-based replacement, and there are many people around the world who are … Continue reading →

IMAGE:Transgenic mouse model was used to target lung mesenchymal cells (green). view more Credit: The Saban Research Institute of Children's Hospital Los Angeles By uncovering the mechanism by which fibrous tissue cells in the lung multiply, researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA), along with colleagues in Mexico and Canada, have identified a promising new approach for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis or IPF- where the disease appears spontaneously and without a known cause - is a severe, chronic lung disease in which the rapid growth of fibrous tissue results in increasingly severe breathing difficulties and a high mortality rate. Excessive signaling of the growth factor TGF- is recognized as a central player in lung fibrosis, and its increased expression has been identified in both IPF patients and experimental models of the disease. However, in addition to its pro-fibrotic effect, TGF- signaling is essential to aspects of other systems, such as appropriate immune response. Therefore, complete therapeutic blockade of TGF- pathway isn't ideal, says the study's principal investigator Wei Shi, MD, PhD, of the Developmental Biology and Regenerative Medicine research program at CHLA. "This is a very complicated signaling pathway, which promotes … Continue reading →

Written by Lidia Dinkova on March 18, 2015 University of Miami stem cell research on generating healthy heart tissue in heart attack survivors is on track to be tested across the US. The National Heart, Lung and Blood Institute, part of federal medical research arm the National Institutes of Health, is to fund the $8 million cost if the trial wins necessary approvals. The trial, the first of this research in humans, is a step toward restoring full heart function in heart attack survivors. The research developed at the UM Miller School of Medicines Interdisciplinary Stem Cell Institute is on combining two types of stem cells to generate healthy heart tissue in heart attack survivors. Scientists have in the past studied using one type of stem cell at a time, a method thats worked OK, said Dr. Joshua Hare, founding director of the UM stem cell institute. But UM research shows that combining two types of stem cells expedites healing and regeneration of healthy heart muscle. We could remove twice the scar tissue than with either cell alone, Dr. Hare said. We had some scientific information that they actually interacted and worked together, so we tested that. It worked. Researchers … Continue reading →